FATE
Fate Therapeutics Inc

6,399
Mkt Cap
$127.89M
Volume
1.51M
52W High
$1.94
52W Low
$0.661
PE Ratio
-0.96
FATE Fundamentals
Price
$1.15
Prev Close
$1.10
Open
$1.11
50D MA
$1.24
Beta
1.69
Avg. Volume
1.76M
EPS (Annual)
-$1.15
P/B
0.61
Rev/Employee
$41,279.50
$9.08
Loading...
Loading...
News
all
press releases
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have...
MarketBeat·16h ago
News Placeholder
More News
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 14.1% in February
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 9,563,527...
MarketBeat·6d ago
News Placeholder
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference
Fate Therapeutics (NASDAQ:FATE) CEO Bob Valamehr outlined the company's clinical and manufacturing strategy for FT819, an off-the-shelf allogeneic CAR T-cell therapy, during a conference fireside...
MarketBeat·8d ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations
Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts...
MarketBeat·24d ago
News Placeholder
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +1.21% and -8.73%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·25d ago
News Placeholder
Earnings Summary: Fate Therapeutics Q4
read more...
Benzinga·25d ago
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has been given a consensus recommendation of "Hold" by the nine research firms that are presently covering the stock, MarketBeat Ratings...
MarketBeat·26d ago
News Placeholder
Fate Therapeutics (FATE) to Release Earnings on Wednesday
Fate Therapeutics (NASDAQ:FATE) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...
MarketBeat·27d ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average - What's Next?
Fate Therapeutics (NASDAQ:FATE) Stock Passes Above 50 Day Moving Average - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have received a consensus recommendation of "Hold" from the nine analysts that are covering the firm, Marketbeat.com reports. One...
MarketBeat·2mo ago
<
1
2
...
>

Latest FATE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.